AbbVie（ABBV）株式概要
研究開発型のバイオ医薬品企業であるアッヴィ社は、世界中で医薬品や治療薬の研究開発、製造、商業化、販売を行っている。 詳細
Last Earnings Call
Q2 2026 · 31 Jul 2026AbbVie (NYSE: ABBV) reported a strong second quarter for 2026, with net revenues of approximately $17 billion, a 10.2% increase year-over-year 1. Adjusted EPS reached $3.65, surpassing the guidance midpoint 1. Growth was driven by Skyrizi (+24%) and Rinvoq (+23.7%), alongside a robust neuroscience portfolio (+20%) 1. Humira sales declined 36.1% as expected 1.
Management raised full-year revenue guidance by $300 million 1. However, adjusted EPS guidance for the full year was set at $13.87–$14.07, factoring in $0.14 dilution from the pending Apogee Therapeutics acquisition 1.
Analyst Consensus vs. Reported Results:
- Revenue: Analyst consensus was approximately $16.7 billion. AbbVie beat this estimate by $300 million 1.
- EPS: Analyst consensus was $3.59. AbbVie beat this estimate by $0.06 1.
Market Reaction
AbbVie's stock rose by approximately 3.2% on July 31, 2026. Analysts attributed the positive reaction primarily to the company’s strong "double-digit" growth in key immunology assets, upward revenue guidance revisions, and optimism surrounding the pipeline, specifically the upcoming subcutaneous Skyrizi launch and the acquisition of Apogee Therapeutics.
ABBV Community Fair Values
Create NarrativeSee what 488 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
AbbVie Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$246.04 |
| 52週高値 | US$267.47 |
| 52週安値 | US$190.75 |
| ベータ | 0.28 |
| 1ヶ月の変化 | -0.82% |
| 3ヶ月変化 | 21.33% |
| 1年変化 | 24.23% |
| 3年間の変化 | 61.68% |
| 5年間の変化 | 111.23% |
| IPOからの変化 | 602.97% |
最新ニュース
ナラティブ更新 • Aug 07
ABBV: Future Returns Will Hinge On Apogee Respiratory Bet
Analysts have nudged their fair value estimate for AbbVie higher to about $273 per share. This reflects refreshed models that factor in Q2 updates, stronger confidence in long term margins, and the potential impact of the Apogee acquisition, while still using a slightly higher discount rate and a modestly lower future P/E assumption.Seeking Alpha • Aug 03
AbbVie: Strong Q2 And New Catalysts Keep Me Bullish
Summary On June 29, AbbVie Inc. stock reached a 52-week high of $267.47. But over the past five days, its shares have fallen 6.2% despite strong Q2 earnings. Rinvoq sales grew 24.5% YoY and 19.2% quarter-over-quarter to about $2.53 billion in Q2. Meanwhile, Elahere, used to treat certain patients with ovarian cancer, generated $211 million in revenue for AbbVie in Q2, up 32.7% year-over-year. In this article, you'll learn why AbbVie, my favorite in immunology, still offers an attractive risk/reward profile. Read the full article on Seeking AlphaRecent updates
ナラティブ更新 • Aug 07
ABBV: Future Returns Will Hinge On Apogee Respiratory Bet
Analysts have nudged their fair value estimate for AbbVie higher to about $273 per share. This reflects refreshed models that factor in Q2 updates, stronger confidence in long term margins, and the potential impact of the Apogee acquisition, while still using a slightly higher discount rate and a modestly lower future P/E assumption.Seeking Alpha • Aug 03
AbbVie: Strong Q2 And New Catalysts Keep Me Bullish
Summary On June 29, AbbVie Inc. stock reached a 52-week high of $267.47. But over the past five days, its shares have fallen 6.2% despite strong Q2 earnings. Rinvoq sales grew 24.5% YoY and 19.2% quarter-over-quarter to about $2.53 billion in Q2. Meanwhile, Elahere, used to treat certain patients with ovarian cancer, generated $211 million in revenue for AbbVie in Q2, up 32.7% year-over-year. In this article, you'll learn why AbbVie, my favorite in immunology, still offers an attractive risk/reward profile. Read the full article on Seeking Alphaナラティブ更新 • Jul 24
ABBV: Future Returns Will Rely On Apogee Deal And Broader Pipeline Execution
AbbVie’s updated analyst price target has increased to $266.89 from $259.46 as analysts factor in recent Q2 preview research, higher modeled profit margins, and a slightly adjusted discount rate and future P/E outlook. Analyst Commentary Recent research commentary around AbbVie points to a broadly constructive tone ahead of Q2 results, with several firms revisiting their models, adjusting P/E assumptions, and updating margin and pipeline expectations.ナラティブ更新 • Jul 10
ABBV: Future Returns Will Depend On Apogee Deal And Broader Immunology Expansion
AbbVie’s refreshed analyst price target framework edges higher to about $259 from roughly $254, with analysts pointing to updated Q2 models, recent target hikes across several firms, and added confidence around the Apogee acquisition’s immunology and respiratory potential as key supports for the revision. Analyst Commentary Recent research on AbbVie centers on two main themes, the refreshed Q2 earnings models and the planned Apogee Therapeutics acquisition.ナラティブ更新 • Jun 23
ABBV: Future Returns Will Hinge On Apogee Deal And Immunology Pipeline
Analysts have made only a modest adjustment to AbbVie’s fair value narrative, reflecting a slightly higher discount rate and updated views on margins and long term P/E in light of the proposed $10.9 billion Apogee Therapeutics deal and its implications for competition and atopic dermatitis market potential. Analyst Commentary Recent research on AbbVie around the proposed US$10.9b Apogee Therapeutics acquisition highlights a mix of optimism about growth opportunities in immunology and atopic dermatitis, alongside caution about execution risk, competition, and valuation.分析記事 • Jun 16
AbbVie (ABBV) Stock Could Be 12.6% Undervalued After CLL14 Trial Update
AbbVie (ABBV) is back in focus after releasing nine year final results from its Phase 3 CLL14 trial, where a fixed duration venetoclax plus obinutuzumab regimen improved progression free survival in untreated CLL patients. See our latest analysis for AbbVie. The latest CLL14 update lands after a mixed few sessions for AbbVie, with the share price slipping 2.7% on the day to $221.59, while still showing a 5.3% 30 day share price return and a 19.9% one year total shareholder return that points...ナラティブ更新 • Jun 06
ABBV: Future Returns Will Depend On Expanding Immunology And IBD Pipeline Execution
AbbVie’s updated analyst price target edges higher to $253.55 from $249.43 as analysts factor in slightly higher profit margin assumptions, modestly lower revenue growth expectations, a reduced discount rate, and a somewhat lower future P/E multiple, with recent research highlighting the depth of the inflammatory bowel disease pipeline and broader R&D optionality. Analyst Commentary Recent Street research on AbbVie shows a mix of optimism and caution, with multiple price target revisions clustered within a relatively tight range and commentary that keeps attention on the inflammatory bowel disease pipeline and broader R&D portfolio.分析記事 • May 15
We Think You Can Look Beyond AbbVie's (NYSE:ABBV) Lackluster Earnings
The market was pleased with the recent earnings report from AbbVie Inc. ( NYSE:ABBV ), despite the profit numbers being...ナラティブ更新 • Apr 23
ABBV: Future Returns Will Rely On Immunology Expansion And Operating Leverage Execution
Analysts made a small upward adjustment to AbbVie’s fair value estimate to about $249. The modest change reflects a mix of slightly higher assumed discount rates and future P/E multiples, alongside recent shifts in Street price targets, including both raises and trims from firms such as Piper Sandler, Guggenheim, Cantor Fitzgerald, Evercore ISI, Citi and UBS, as well as fresh bullish initiations from Canaccord, RBC Capital and Barclays.ナラティブ更新 • Apr 08
ABBV: Future Returns Will Hinge On Immunology Encore And Operating Leverage Execution
Analysts have made a modest upward adjustment to AbbVie’s price target, reflecting updated views on its immunology pipeline potential, operating leverage, and the ongoing debate about whether recent share underperformance and selloffs adequately reflect competitive risks. Analyst Commentary Recent research on AbbVie highlights a split view, with some analysts focusing on the upside from the immunology pipeline and operating leverage, while others point to valuation and competitive questions after a period of share underperformance.ナラティブ更新 • Mar 24
ABBV: Future Returns Will Hinge On Immunology Encore Outweighing Competitive Concerns
Narrative Update The analyst price target for AbbVie has been adjusted slightly higher to reflect a fair value move to about $249. Analysts point to early stage indication expansion, operating leverage potential, and ongoing immunology pipeline developments, even as some firms flag emerging competition and a more balanced risk and reward profile.ナラティブ更新 • Mar 10
ABBV: Future Returns Will Depend On Immunology Encore And Deal Optionality Uncertainty
The analyst price target for AbbVie edges higher to align with our fair value shift from $248.29 to $248.86, as analysts highlight ongoing indication expansion in immunology, potential operating leverage, and multiple expansion drivers, even as some firms note emerging competition and a more balanced risk and reward profile. Analyst Commentary Recent research on AbbVie reflects a split view, with some analysts pointing to upside tied to immunology growth and pipeline execution, while others flag competition risk and a more balanced risk and reward profile at current levels.ナラティブ更新 • Feb 22
ABBV: Future Returns Will Rely On Immunology Encore And Evolving Deal Optionality
Our updated AbbVie narrative reflects a modest price target increase to about $248 per share, as analysts point to potential operating leverage, room for P/E multiple expansion, and a pipeline of proof-of-concept and immunology programs that could support slightly higher revenue growth assumptions, even as margin expectations are trimmed. Analyst Commentary Recent research shows a mix of optimism and caution around AbbVie, with several firms adjusting price targets and ratings as they reassess execution risks, competitive pressures, and the potential impact of the pipeline on valuation.ナラティブ更新 • Feb 07
ABBV: Future Returns Will Depend On Immunology Pipeline Clarity And M&A Uncertainty
Analysts have trimmed their price targets for AbbVie by a small amount. This reflects slightly lower revenue growth and P/E assumptions, while also incorporating a modestly higher profit margin and recent mixed research views around competition and pipeline visibility.ナラティブ更新 • Jan 24
ABBV: Future Returns Will Hinge On Post-Humira Immunology And Deal Optionality
Analysts have nudged their price target for AbbVie slightly higher to reflect a fair value estimate of about $245 per share, supported by updated assumptions for revenue growth, profit margins, and a modestly lower future P/E. Recent research highlights both increased price targets and more cautious views around competition and the sustainability of outperformance in key immunology drugs.ナラティブ更新 • Jan 09
ABBV: Future Returns Will Depend On Post-Humira Immunology And Pipeline Execution
Analysts have trimmed their AbbVie fair value estimate by about $0.10 per share to roughly $244.56. This reflects a mix of slightly higher risk assumptions, modestly adjusted revenue and margin expectations, and a more balanced set of views after recent downgrades and price target changes that suggest outperformance is already well reflected in the current share price.分析記事 • Jan 08
AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73
AbbVie Inc. ( NYSE:ABBV ) will increase its dividend from last year's comparable payment on the 17th of February to...ナラティブ更新 • Dec 21
ABBV: Future Returns Will Hinge On Post-Humira Immunology And Pipeline Execution
Analysts have nudged our AbbVie fair value estimate slightly higher, from $243.55 to $244.68. This reflects modestly stronger long term revenue growth expectations for key immunology franchises and pipeline assets, partially offset by slightly lower margin assumptions and a broadly constructive but mixed backdrop of recent price target revisions and rating changes across the Street.ナラティブ更新 • Dec 07
ABBV: Future Performance Will Depend On Extended Exclusivity And Pipeline Execution
Analysts have nudged their average price target on AbbVie modestly higher to reflect a wave of target increases into the mid 240s to low 260s dollar range, supported by stronger visibility into Skyrizi and Rinvoq driven growth, extended Rinvoq exclusivity, and a more favorable large cap biopharma backdrop despite mixed ratings changes. Analyst Commentary Recent research paints a generally constructive picture on AbbVie, with most price target revisions skewing higher even as some firms move to the sidelines.分析記事 • Dec 02
AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.73
The board of AbbVie Inc. ( NYSE:ABBV ) has announced that it will be paying its dividend of $1.73 on the 17th of...ナラティブ更新 • Nov 23
ABBV: Future Performance Will Depend On Pipeline Expansion And Patent Protections
AbbVie’s analyst price target has increased modestly from $241.29 to $243.55. Analysts cite resilient performance in immunology products, extended Rinvoq exclusivity, and improving fundamentals as key drivers of sentiment.分析記事 • Nov 18
AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73
The board of AbbVie Inc. ( NYSE:ABBV ) has announced that it will be paying its dividend of $1.73 on the 17th of...株主還元
| ABBV | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | -2.0% | 6.3% | 4.2% |
| 1Y | 24.2% | 40.9% | 20.6% |
業界別リターン: ABBV過去 1 年間で40.9 % の収益を上げたUS Biotechs業界を下回りました。
リターン対市場: ABBV過去 1 年間で20.6 % の収益を上げたUS市場を上回りました。
価格変動
| ABBV volatility | |
|---|---|
| ABBV Average Weekly Movement | 4.1% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: ABBV 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: ABBVの 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2012 | 57,000 | Robert Michael | www.abbvie.com |
研究開発型のバイオ医薬品企業であるアッヴィ社は、世界中で医薬品や治療法の研究開発、製造、商業化、販売を行っている。同社は、自己免疫疾患治療薬Skyrizi、炎症性疾患治療薬Rinvoq、成人血液がん治療薬Imbruvica、血液がん治療薬Venclexta、各種がん治療薬Elahere、リンパ腫治療薬Epkinly、肺がん治療薬Emrelisを提供している。また、顔面注射剤、形成・再生医療、ボディライン形成、スキンケア製品も提供している。ボトックス・コスメティックは、目尻のシワ、カラスの足跡、額のシワ、板状筋の治療に、ジュビダーム・コレクションは、こめかみ、目の下、頬、あご、唇、下顔面のボリュームの減少に効く；統合失調症、双極性障害、うつ病性障害を治療するVraylar、パーキンソン病を治療するDuodopa、片頭痛を治療するUbrelvy、エピソード性片頭痛と慢性片頭痛を治療するQulipta、運動ゆらぎを治療するVyalev、慢性片頭痛、過活動膀胱、痙縮、頸部ジストニアなどを治療するBotox Therapeuticがある。さらに、視覚障害治療薬オズールデックス、開放隅角緑内障や高眼圧症患者の眼圧上昇を抑制するルミガン／ガンフォート、アルファガン／コンビガン、その他リフレッシュ／オプティブ、ゼン、デュリスタ、レスタシスなどのアイケア製品を提供している。さらに、慢性C型肝炎ウイルス遺伝子型1～6型感染症治療薬マヴィレット、膵酵素治療薬クレオン、便秘を伴う過敏性腸症候群および慢性特発性便秘症治療薬リンゼス/コンステラを提供している。同社は2012年に法人化され、イリノイ州ノースシカゴに本社を置いている。
AbbVie Inc. 基礎のまとめ
| ABBV 基礎統計学 | |
|---|---|
| 時価総額 | US$434.78b |
| 収益（TTM） | US$6.27b |
| 売上高(TTM) | US$64.39b |
69.3x
PER（株価収益率6.8x
P/SレシオABBV は割高か？
公正価値と評価分析を参照収益と収入
| ABBV 損益計算書（TTM） | |
|---|---|
| 収益 | US$64.39b |
| 売上原価 | US$17.52b |
| 売上総利益 | US$46.87b |
| その他の費用 | US$40.60b |
| 収益 | US$6.27b |
直近の収益報告
Jun 30, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | 3.55 |
| グロス・マージン | 72.79% |
| 純利益率 | 9.74% |
| 有利子負債／自己資本比率 | -1,203.9% |
ABBV の長期的なパフォーマンスは？
過去の実績と比較を見る| AbbVie 配当日 | |
|---|---|
| 配当落ち日 | Jul 15 2026 |
| 配当支払日 | Aug 14 2026 |
| 配当落ちまでの日数 | 25 days |
| 配当支払日までの日数 | 5 days |
ABBV 配当は確実ですか？
ABBV 配当履歴とベンチマークを見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/09 04:29 |
| 終値 | 2026/08/07 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
AbbVie Inc. 20 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。51
| アナリスト | 機関 |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Luisa Hector | Berenberg |